Paradigm Biopharma raises the stakes in osteoarthritis pain reduction

Biotech company Paradigm Biopharmaceuticals (ASX: PAR) has announced further progress in its bid to develop a definitive pain reduction treatment for both elite athletes and sufferers of osteoarthritis. Earlier today, Paradigm reported that it had achieved a 60% reduction in osteoarthritis pain as part of its ongoing TGA-approved special access scheme that has attracted several … Continue reading Paradigm Biopharma raises the stakes in osteoarthritis pain reduction